Pharma’s big push for a new generation of obesity drugs
Rivals to Novo Nordisk and Eli Lilly are piling in
FIVE YEARS ago Novo Nordisk was a boring Danish drugmaker whose diabetes medications were reliably profitable. The only time the company made headlines was when it was caught up in complaints about the high cost of insulin. Then in 2021 a trial of a higher dose of its diabetes drug, Ozempic, showed that people taking it lost weight. A great deal of weight—up to 15% of their body mass. Excitement about the drug has kept Novo Nordisk in the headlines. Its market value has nearly quadrupled in the past five years. Earlier this month it reached $444bn, handbagging LVMH, a purveyor of luxury goods, off its perch as Europe’s most valuable company. Novo Nordisk’s main rival, Eli Lilly, which has a similar drug called Mounjaro (tirzepatide), is worth $522bn, more than four times what it was at the start of 2019.
This article appeared in the Business section of the print edition under the headline “Pharma’s plus-size endeavours”
Business September 30th 2023
- Will the auto workers’ strike jeopardise Joe Biden’s manufacturing boom?
- Hollywood’s strike enters its final act, as writers reach a deal
- Can Europe’s power grid cope with the green transition?
- Ties between foreign businesses and China go from bad to worse
- What if Hollywood blockbusters were remade as workplace dramas?
- Pharma’s big push for a new generation of obesity drugs
- Customer service is getting worse—and so are customers
From the September 30th 2023 edition
Discover stories from this section and more in the list of contents
Explore the editionDiscover more
Could seaweed replace plastic packaging?
Companies are experimenting with new ways to reduce plastic waste
Has Sequoia Capital outgrown its business model?
Venture capital’s hardiest perennial gets back to its roots
On stupid rules and quick wins
Why every boss can benefit from asking employees what most infuriates them
TikTok wants Western consumers to shop like the Chinese
It still has some convincing to do
Will the trouble ever end for Volkswagen and its rivals?
From strikes to Trump tariffs, calamities abound
After Northvolt’s failure, who will make Europe’s EV batteries?
The continent looks ever more reliant on Asian producers